Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06084936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Name: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma — clinical trial record (NCT06084936)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GLOBRYTE

StatusRecruiting

PhasePhase 3

SponsorHoffmann-La Roche

Started2023-10-22

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Amendment history 1 change detected by DataLookout

2026-08-06

Trial sites expanded: 77 → 82 locations

Trial Details

NCT Number	NCT06084936
Lead Sponsor	Hoffmann-La Roche
Conditions	Lymphoma
Enrollment	182 participants
Start Date	2023-10-22
Primary Completion	2027-08-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-03